Lorbriqua tablet (Lorlatinib)

Precautions of Lorbriqua Tablet:

• Pregnancy and Breastfeeding: Lorbriqua can harm an unborn baby. Women of childbearing potential should use effective non-hormonal contraception during treatment and for at least 6 months after the final dose. Men with female partners of childbearing potential should use effective contraception during treatment and for at least 3 months after the final dose. Do not breastfeed during treatment and for 7 days after the final dose.
• Liver and Kidney Function: Use with caution; dosage adjustments may be necessary.
• CNS Effects: Monitor for signs of cognitive or mood changes.
• Heart Monitoring: Regular ECGs may be required to monitor heart rhythm.
• Lipid Levels: Monitor cholesterol and triglyceride levels before and during treatment.
• Blood Pressure: Monitor blood pressure regularly; manage hypertension as needed.
• Blood Sugar Levels: Monitor for signs of hyperglycemia; manage as appropriate.

Uses of Lorbriqua Tablet:

Lorbriqua is indicated for the treatment of:

• ALK-positive metastatic NSCLC in patients who have progressed on or are intolerant to first- and second-generation ALK inhibitors.
• Brain metastases associated with ALK-positive NSCLC, due to its ability to cross the blood-brain barrier.

Side Effects of Lorbriqua Tablet:

Patients taking Lorbriqua may experience side effects. Regular monitoring by a healthcare provider is essential.

• Common Side Effects:

• Swelling in arms, legs, hands, and feet (edema)
• Numbness or tingling in joints or limbs (peripheral neuropathy)
• Weight gain
• Cognitive effects (e.g., forgetfulness, confusion)
• Fatigue
• Difficulty breathing
• Joint pain
• Diarrhea
• Mood changes (e.g., depression, irritability)
• High cholesterol and triglyceride levels
• Cough

• Serious Side Effects:

• Central nervous system effects, including seizures, hallucinations, and mood changes.
• Heart problems, such as slow or abnormal heartbeats.
• Lung problems, including inflammation leading to breathing difficulties.
• High blood pressure (hypertension).
• High blood sugar levels (hyperglycemia).

Note: Lorbriqua may cause decreased fertility in males. Discuss fertility preservation options with your healthcare provider before starting treatment

FAQs of Lorbriqua Tablet:

Q1: Can Lorbriqua be used as a first-line treatment for ALK-positive NSCLC?

Lorbriqua is typically used after progression on first- and second-generation ALK inhibitors. Consult your oncologist for personalized treatment options.

Q2: How should I store Lorbriqua tablets?

Store at room temperature between 20°C to 25°C (68°F to 77°F) in the original container. Keep out of reach of children.

Q3: What should I do if I miss a dose?

Take the missed dose as soon as you remember unless it's within 4 hours of your next scheduled dose. Do not take two doses at the same time.

Q4: Can I consume grapefruit while taking Lorbriqua?

Avoid grapefruit and grapefruit juice as they can affect the metabolism of Lorbriqua and increase the risk of side effects.

Interactions of Lorbriqua Tablet:

Lorbriqua may interact with several medications:

• CYP3A Inducers: Avoid concomitant use with strong CYP3A inducers as they can decrease Lorbriqua plasma concentrations.
• CYP3A Substrates: Lorbriqua may increase plasma concentrations of CYP3A substrates, potentially leading to increased toxicity.
• Other Medications: Inform your healthcare provider about all medications, including over-the-counter drugs and herbal supplements, to avoid potential interactions.